Xilaplus AF comprimidos
Ref 1291414Model Xilaplus AF tablets
Active
CE MDR
Valid until
14 Nov 2029
FDA recalls
Not applicable
Documents
Trust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| European Union | CE/MDR | NumberMDR 00064-A | Date27 Mar 2025 | StatusActive |
Certificates
- MDR 00064-A Active
Quality management system EU MDR
- Certifier
- KIWA CERMET ITALIA S.P.A. 0476
- Issued
- 27 Mar 2025
- Expires
- 14 Nov 2029
- MDR 00064-B Active
Technical documentation EU MDR
- Certifier
- KIWA CERMET ITALIA S.P.A. 0476
- Issued
- 27 Mar 2025
- Expires
- 14 Nov 2029
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
European Union — CE/MDR Active
Specification
- Device Name
- Xilaplus AF tablets
- Model / Reference
- Xilaplus AF tablets, 1291414
- Primary DI / UDI-DI
- 08436593830052
- Basic UDI-DI
- 843659383XIA653NF
- Direct Marketing DI
- 08436593830052
- EMDN Code
- G0402 Orally administered devices for appetite control and reduction of intestinal absorption
- Device Class
- Class III
- EU market of registration
- Spain
Manufacturer details
- EUDAMED SRN
- ES-MF-000000797
Other devices from Noventure S.L.U.
Properties
Other properties (13)
- Sterile: No
- Implantable: No
- Reusable: No
- Contains Latex: No
- Reprocessed: No
- CMR Substance: No
- Human-derived: No
- Human Tissues: No
- Animal Tissues: No
- Endocrine Disruptor: No
- Administering Medicine: No
- Measuring Function: No
- Incorporates Medicinal Product: No